Answers are grounded in this paper and cite their sources.
Quantitative non‐invasive imaging of target structures in the human central nervous system provided by positron emission tomography (PET) permits investigation of the relationship between molecular events and pharmacological effects in living humans. Due to their prominent role in opiate and stimulant drug misuse and dependence, as well as in nociceptive signaling, µ‐ and κ‐opioid receptors are potential targets for advances in neuro(psycho)pharmacological treatment of these illnesses and syndromes. In this review, we describe recent developments in specific positron emitting radiopharmaceuticals for these opioid receptor subclasses. Implications for further advances and clinical applications of the labeled ligands are discussed. Drug Dev. Res. 67:890–904, 2006.
No takes yet. Share an insight, caveat, or question.
Henriksen et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: